NCT02955940

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

An Open-Label, Multicenter, Rollover Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an Incyte-sponsored study of ruxolitinib that has reached its study objectives or has been terminated. This study will also provide another mechanism for reporting adverse events related to study drug safety.

Conditions

• Pancreatic Cancer
• Colorectal Cancer (CRC)
• Breast Cancer
• Lung Cancer

Interventions

Type	Name	Description
DRUG	Ruxolitinib	5 mg BID
DRUG	Capecitabine	Capecitabine at the same dose provided in the parent study at the time of the rollover.
DRUG	Regorafenib	Regorafenib at the same dose provided in the parent study at the time of the rollover.

Timeline

• Start date: 2016-11-30
• Primary completion: 2027-09-30
• Completion: 2027-09-30
• First posted: 2016-11-04
• Last updated: 2025-12-17

Locations

9 sites across 2 countries: United States, Poland